Positive Phase II results for anti-smoking vaccine

Looking to quit smoking? Nabi Biopharmaceuticals may have just the thing to help. The company has successfully completed a Phase IIb trial of NicVax, which is being developed to treat nicotine addiction and prevent smoking relapse. According to data the company presented at a meeting of the American Heart Association, significant trends were seen at twelve months for both smoking cessation and long-term smoking abstinence. Dr. Leslie Hudson, Interim President and CEO of Nabi, said that the company will use the data to continue its hunt for a partner on the drug.

- see this release from Nabi

Related Articles:
Nabi sells unit for $185M, plans Maryland move. Report
Nabi axes 33 jobs in restructuring. Report
Nabi CEO walks after hedge fund balks. Report
Nabi vows to push ahead with vaccine work. Report
Nabi ready for a deal after NicVAX hits endpoint. Report